Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2024-03-12 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is specifically a '정정신고' (Correction Report) regarding previously granted stock options. This type of filing relates to changes in capital structure and equity-based compensation, which falls under the category of share issues or capital changes. Given the specific nature of stock option grants and their impact on share capital, 'SHA' (Share Issue/Capital Change) is the most appropriate classification.
2024-03-12 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a correction (정정신고) to a previous filing. It details changes to the number of recipients and the number of shares granted for stock options. This type of disclosure regarding capital structure and equity-based compensation for employees/directors falls under general regulatory filings as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for new capital issuance). Therefore, it is classified as a Regulatory Filing (RNS).
2024-03-12 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from a Korean company (TiumBio) regarding the 'Acquisition of convertible bonds before maturity'. This type of filing details changes to the company's capital structure and debt obligations, specifically the repurchase of convertible bonds. According to the provided definitions, this falls under 'Capital/Financing Update' (CAP) as it relates to financing activities and changes in capital structure.
2024-02-29 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (면역항암제 TU2218 식약처 임상1/2상 임상시험계획 변경승인 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (TiumBio) submitted to the Korea Exchange (KRX) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). Specifically, it details an application for an amendment to a clinical trial plan (임상시험계획 변경승인신청) for an immunotherapy drug. Since this is a formal regulatory disclosure of a material business event that does not fit into specific categories like financial reports, dividends, or board changes, it is classified as a general regulatory filing.
2024-02-23 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (TiumBio) reporting a significant change in revenue or profit structure (30% or more). This type of disclosure is a standard requirement for listed companies in Korea to announce preliminary financial results before the final audit is completed. Since it provides key financial highlights and explains the reasons for the variance, it falls under the 'Earnings Release' category. FY 2023
2024-02-15 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. This type of filing is required when an entity acquires a significant stake (typically 5% or more) in a publicly traded company. In the provided taxonomy, this corresponds to a 'Major Shareholding Notification' (MRQ), which tracks changes in significant ownership levels.
2024-01-02 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.